The Inherited Skin Disorders drugs in development market research report provides comprehensive information on the therapeutics under development for Inherited Skin Disorders, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Inherited Skin Disorders. Buy the report here.

Smarter leaders trust GlobalData

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Inherited Skin Disorders and features dormant and discontinued products.

GlobalData tracks 19 drugs in development for Inherited Skin Disorders by 17 companies/universities/institutes. The top development phase for Inherited Skin Disorders is preclinical with six drugs in that stage. The Inherited Skin Disorders pipeline has 18 drugs in development by companies and one by universities/ institutes. Some of the companies in the Inherited Skin Disorders pipeline products market are: DermaXon, Neurodon and Biogenera.

The key targets in the Inherited Skin Disorders pipeline products market include Cytochrome P450 26A1 (hP450RAI or Cytochrome P450RAI or Retinoic Acid 4 Hydroxylase or Cytochrome P450 Retinoic Acid Inactivating 1 or Retinoic Acid Metabolizing Cytochrome or CYP26A1 or EC 1.14.), Cytochrome P450 26B1 (Cytochrome P450 26A2 or Cytochrome P450 Retinoic Acid Inactivating 2 or Retinoic Acid Metabolizing Cytochrome or CYP26B1 or EC 1.14.), and Filaggrin (FLG).

The key mechanisms of action in the Inherited Skin Disorders pipeline product include Cytochrome P450 26A1 (hP450RAI or Cytochrome P450RAI or Retinoic Acid 4 Hydroxylase or Cytochrome P450 Retinoic Acid Inactivating 1 or Retinoic Acid Metabolizing Cytochrome or CYP26A1 or EC 1.14.) Inhibitor with two drugs in Preclinical. The Inherited Skin Disorders pipeline products include four routes of administration with the top ROA being Topical and seven key molecule types in the Inherited Skin Disorders pipeline products market including Small Molecule, and Gene Therapy.

Inherited Skin Disorders overview

Inherited skin disorders encompass a diverse group of genetic conditions affecting the skin’s structure, function, or development. These disorders can manifest as a range of symptoms, including abnormalities in pigmentation, texture, or the presence of certain growths or lesions. Examples of inherited skin disorders include epidermolysis bullosa, ichthyosis, and albinism. These conditions often result from mutations in specific genes responsible for skin development and maintenance.

For a complete picture of Inherited Skin Disorders’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.